OOIR: Observatory of International Research

Papers

(The H4-Index of Neurology-Neuroimmunology & Neuroinflammation is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	167
MOG IgG3-Subclass Antibodies in MOG-Associated Disease	94
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	92
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	80
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	80
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	71
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	70
Antibody-Negative Autoimmune Encephalitis	70
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	69
Elevated ITGAX/CD11c in CSF-Derived Extracellular Vesicles Reflects Disability Progression in Multiple Sclerosis	67
Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells	64
Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	63
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	63
Peripheral HLA-DR ^hi CD141 ⁺ Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis	62
Treatment With Erythropoietin for Patients With Optic Neuritis	61
Plasma N -Glycan Profiling Enhances Diagnostic Precision in Multiple Sclerosis, AQP4-Ab NMOSD, and MOGAD	61
Acute Paresthesia and Ataxia in a Child	61
Should We Measure CSF Complement Levels in Patients With MOGAD?	60
CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity	58
Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	56
TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency	53
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis	51
Toward Precision Phenotyping of Multiple Sclerosis	51
Systematic Review and Meta-Analysis of the Clinical Features Associated With Seronegative Autoimmune Encephalitis	50
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	49

Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	48
Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies	47
Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers	47
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	47
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis	46
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis	45
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies	44
Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review	43
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease	41
Applying the Supporting Features for MOGAD Diagnosis to Patients With Multiple Sclerosis	39
Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders	38
Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis	37